Supplementary information

Correlation of patient serum IgG, IgA and IgM antigen binding with COVID-19 disease severity using multiplexed SARS-CoV-2 antigen microarray and maintained relative IgA and IgM antigen binding over time

Marie Le Berre,¹ Terézia Paulovčáková,¹ Carolina De Marco Verissimo,² Seán Doyle,³ John P. Dalton,² Claire Masterson,⁴ Eduardo Ribes Martínez,^{5,6} Laura Walsh,⁷ Conor Gormley,⁸ John G. Laffey,^{4,9} Bairbre McNicholas,^{4,9} Andrew J. Simpkin,¹⁰ Michelle Kilcoyne^{1,*}

¹ Carbohydrate Signalling Group, Discipline of Microbiology, School of Chemical and Biological Sciences, University of Galway, University Road, Galway, H91 TK33, Ireland.

² Molecular Parasitology Lab, Centre for One Health and Ryan Institute, School of Natural Science, University of Galway, University Road, Galway, H91 TK33, Ireland.

³ Department of Biology, Maynooth University, Maynooth, Co. Kildare, Ireland.

⁴ School of Medicine, and Regenerative Medicine Institute (REMEDI) at CÚRAM Centre for Research in Medical Devices, University of Galway, Galway, Ireland.

⁵ Lambe Institute for Translational Research, School of Medicine, College of Medicine, Nursing and Health Sciences, University of Galway, Galway, Ireland.

⁶ Current address: Gene Center, Ludwig-Maximilians University of Munich, Feodor-Lynen-Str. 25, 81377 Munich, Germany

⁷ University College Dublin, Belfield, Dublin 4, D04 V1W8, Ireland.

⁸ Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland.

⁹ Department of Anaesthesia and Intensive Care Medicine, University Hospital Galway, Saolta University Hospital Group, Newcastle Road, Galway, Ireland.

¹⁰ School of Mathematical and Statistical Sciences, University of Galway, University Road, Galway, H91 TK33, Ireland.

* Corresponding author. Email: michelle.kilcoyne@nuigalway.ie

Table of contents

Fig. S1. Purified SARS-CoV-2-positive patient (severe disease) serum IgG, IgA and IgM and the IgG-, IgM- and IgA-depleted flow through printed on a Nexterion® slide H surface and incubated with fluorescently labelled anti-isotype antibodies in different subarrays.

Fig. S2. Bar chart representing the binding intensity of His-tagged recombinant SARS-CoV-2 protein antigens to printed serum antibody isotypes purified from one SARS-CoV-2-positive patient (severe disease) serum sample.

Fig. S3. Antigen microarray print optimisation.

Fig. S4. Bar charts representing the binding intensity of diluted serum (1/100 in PBS-T) and purified serum antibody isotypes from a SARS-CoV-2-positive patient detected by fluorescently-labelled anti-isotype antibodies.

Fig. S5. Glycosylation profiling of SARS-CoV-2 antigens produced in mammalian (HEK) and insect (Sf21) cells.

Fig. S6. Dynamic binding of patient serum antibody isotypes over short term for severe COVID-19 disease.

Fig. S7. Dynamic binding of patient serum antibody isotypes over medium term for severe and mild COVID-19 disease.

Fig. S8. Variation in IgG binding to (**A**) Npro Full Ecoli and (**B**) S2Frag Ecoli for a subset of patient samples.

Table S1. Recombinant SARS-CoV-2 proteins used to construct the antigen (Ag) microarray.**Table S2.** Lectins used for recombinant SARS-CoV-2 proteins glycoprofiling.

Table S3. Supplementary Excel file containing all antibody isotype binding to SARS-CoV-2 antigens from antigen microarray experiments and patient clinical data.

Table S4. Significance of correlation analysis for first sampling point serum IgG samples binding to antigens with low intensity compared to non-COVID-19 samples.

Table S5. Significance of correlation analysis for first sampling point serum IgG samples binding to antigens with high intensity compared to non-COVID-19 samples.

Table S6. Significance of correlation analysis for first sampling point serum IgA samples binding to antigens with low intensity compared to non-COVID-19 samples.

Table S7. Significance of correlation analysis for first sampling point serum IgA samples binding to antigens with high intensity compared to non-COVID-19 samples.

Table S8. Significance of correlation analysis for first sampling point serum IgM samples binding to antigens with low intensity compared to non-COVID-19 samples.

Table S8. Significance of correlation analysis for first sampling point serum IgM samples

 binding to antigens with high intensity compared to non-COVID-19 samples.

Table S10. Serum sample information including follow up samples.



в



Fig. S1. Purified SARS-CoV-2-positive patient (severe disease) serum IgG, IgA and IgM and the IgG-, IgM- and IgA-depleted flow through printed on a Nexterion® slide H surface and incubated with fluorescently labelled anti-isotype antibodies in different subarrays. IgG was printed at 3 and 1.5 mg/mL, IgA at 1 mg/mL and IgM at 0.3 mg/mL and the flow through (FT3) at 2.5 and 1.25 mg/mL. (**A**) Bar chart representing the binding intensity of the fluorescently-labelled anti-isotype antibodies binding to immobilised IgG, IgA and IgM, incubated at 1, 2, and 1 µg/mL, respectively. (**B**) Scanned image of a subarray depicting the printed serum IgG, IgA, IgM and Ig-depleted FT3 incubated with fluorescently labelled anti-IgG antibody. The cross-reactivity of the anti-IgG antibody for IgA and IgM can be clearly observed and remaining IgGs were also detected in the Ig-depleted flow through FT3.



Fig. S2. Bar chart representing the binding intensity of His-tagged recombinant SARS-CoV-2 protein antigens to printed serum antibody isotypes purified from one SARS-CoV-2-positive patient (severe disease) serum sample. The serum antibody isotype microarray slides were incubated with a panel of antigens: NP Ecoli at 67 and 27 μ g/mL, 3CLike Ecoli at 70 μ g/mL and B117 RBD HEK at 17 μ g/mL. Antigen binding was detected by incubation with fluorescently-labelled anti-His antibody at 1 μ g/mL.



Fig. S3. Antigen microarray print optimisation. (**A**) Serum antibody isotype binding to SARS-CoV-2 antigens on microarray detected by either tetramethylrhodamine- (TRITC-) or AlexaFluor® 555- (AF555-)labelled anti-isotype antibodies. (**B**) Representative image of a subarray from an antigen microarray slide incubated with SARS-CoV-2-positive patient serum followed by detection with anti-IgG-AF555.



Fig. S4. Bar charts representing the binding intensity of diluted serum (1/100 in PBS-T) and purified serum antibody isotypes from a SARS-CoV-2-positive patient detected by fluorescently-labelled anti-isotype antibodies. Binding comparisons of (**A**) serum and purified serum IgG, (**B**) serum and purified IgA, and (**C**) serum and purified IgM. Comparisons of serum versus purified antibody isotype detection are shown across two charts to allow visualisation of lower serum antibody isotype binding to certain antigens.



Fig. S5. Glycosylation profiling of SARS-CoV-2 antigens produced in mammalian (HEK) and insect (Sf21) cells. Unsupervised clustering of binding intensities of a panel of fluorescently-labelled lectins to recombinant SARS-CoV-2 proteins printed on the antigen microarray. The lectin LFA was non-functional in this format and was disregarded. Normalised data were subjected to unsupervised, Euclidean distance, complete linkage clustering.



Fig. S6. Dynamic binding of patient serum antibody isotypes over short term for severe COVID-19 disease. Bar charts represent binding intensity data for serum (A,B) IgG, (C,D) IgA, and (E,F) IgM binding to SARS-CoV-2 antigens for patient 203-0021 (**A,C,D**; M, 61-65 years) and 203-0078 (**B,D,F**; F, 31-35 years) at 15 and 17 days, and 9 and 16 days post-first symptom onset, respectively.



Fig. S7. Dynamic binding of patient serum antibody isotypes over medium term for severe and mild COVID-19 disease. Bar charts represent binding intensity data for serum (A,B) IgG, (C,D) IgA, and (E,F) IgM binding to SARS-CoV-2 antigens for patient 203-0024 (**A,C,D**; severe, F, 66-70 years) and 203-0078 (**B,D,F**; mild, M, 61-65 years) at 31 and 34 days, and 25 and 59 days post-first symptom onset, respectively.



Fig. S8. Variation in IgG binding to (A) Npro Full Ecoli and (B) S2Frag Ecoli for a subset of patient samples.

Table S1. Recombinantly expressed SARS-CoV-2 proteins used to construct the antigen (Ag) microarray, the Ag code, approximate print concentration (mg/mL), molecular mass observed by SDS-PAGE, expression system, protein sequence expressed, buffer that the protein was supplied in, supplier, and catalogue number. MPL, Molecular Parasitology Lab; RB, RayBiotech; R&D, R&D Systems.

Ag code	Protein Ag	Print conc	Mr (kDa)	Expression	Sequence	Buffer	Supplier	Cat. no.
Npro Full Ecoli	Nucleocapsid protein, full length	0.06	50	E. coli	2-1269	PBS + 500 mM imidazole	MPL	
3CLike Ecoli	3C-like protease	0.24	34	E. coli	1-306	PBS	MPL	-
Spro Ecoli	Spike protein, full length	0.12	135	E. coli	10-1282	Potassium phosphate + 0.1% Sarkosyl, pH 7.4	MPL	-
S1Frag Ecoli	Spike protein fragment 1	0.15	75	E. coli	10-686	Potassium phosphate + 0.1% Sarkosyl, pH 7.4	MPL	-
S2Frag Ecoli	Spike protein fragment 2	0.06	54	E. coli	687-1283	Potassium phosphate + 0.1% Sarkosyl, pH 7.4	MPL	-
S2Pri Ecoli	Spike protein fragment 2 prime region	0.01	38	E. coli	816-1283	PBS+0.05% Sarkosyl	MPL	-
NP Ecoli	Nucleocapsid protein	0.95	50	E. coli	Met1-Ala419	PBS	RB	230-01104
NP HEK	Nucleocapsid protein	0.6	50-60	HEK293	Met1-Ala419	PBS	RB	230-30164
NP Sf21	Nucleocapsid protein	0.5	44-53	Sf21	Met1-Ala419	PBS	R&D	10474-CV
S1 HEK	S1 subunit protein	0.5	106-121	HEK293	Val16-Pro681	PBS with trehalose	R&D	10569-CV
S1 Sf21	S1 subunit protein	0.2	78-92	Sf21	Val16-Pro681	PBS with trehalose	R&D	10522-CV
B117 RBD HEK	B.1.1.7 receptor binding domain	0.25	34-38	HEK293	Arg319-Phe541	PBS with trehalose	R&D	10730-CV
S1 Full HEK	S1 subunit protein, full length	0.45	120	HEK293	Val16-Gln690	PBS	RB	230-30161

	Membrane glycoprotein,	0.17				PBS + 200 mM		
MP Ecoli	C-terminal		15	E. coli	Arg101-Gln222	imidazole	RB	230-01124

Lectin	Abbreviation	Major binding specificity	Conc.
Griffonia simplicifolia lectin	GSL-I-B4	Terminal α-linked Gal	10
Vigna radiate lectin	VRA	Terminal α-linked Gal	10
Artocarpus integrifolia agglutinin	AIA	Gal- β -(1 \rightarrow 3)-GalNAc (T-antigen), β -(1 \rightarrow 6)-linked Gal, sialylation independent	15
Arachis hypogaea lectin	PNA	Gal-β-(1→3)-GalNAc (T-antigen) >GalNAc>Lac>Gal, terminal β-Gal)	10
Sophora japonica lectin	SJA	β-linked GalNAc>Gal	10
<i>Wisteria floribunda</i> agglutinin	WFA	GalNAc (GalNAc- α -(1 \rightarrow 6)- Gal>GalNAc- α -(1 \rightarrow 3)-R GalNAc (Forsmann antigen) >GalNAc>>Lac>Gal, chondroitin sulfate	10
Phaseolus vulgaris lectin	PHA-L	tri-, tetra-antennary β-Gal/Gal-β-(1→4)- GlcNAc	10
<i>Griffonia simplicifolia</i> lectin	GSL-II	GlcNAc	10
Triticum vulgaris lectin	WGA	NeuAc/GlcNAc	10
Limax flavus lectin	LFA	NeuAc/NeuGc	10
Maackia amurensis agglutinin	MAA	Neu- α -(2 \rightarrow 3)-Gal = Gal-3-SO ₄ >Lac	15
Sambucus nigra agglutinin I	SNA-I	Neu- α -(2 \rightarrow 6)-Gal(NAc)>Lac, GalNAc >Gal	10
Canavalia ensiformis (jack bean lectin)	Con A	α-linked Man>Glc>GlcNAc	10
Hippeastrum hybrid lectin	ННА	Man-α-(1,3)-Man-α-(1,6)-	10
Lotus tetragonolobus lotus lectin	LTA	α -(1 \rightarrow 3)-linked Fuc	10
Ulex europaeus agglutinin I	UEA-I	α -(1 \rightarrow 2)-linked Fuc, H type 2 antigen	10

Table S2. Lectins used for recombinant SARS-CoV-2 proteins glycoprofiling, their binding specificities and concentrations used (μ g/mL).

		IgG	
Predictors	Estimates	CI	р
(Intercept)	77.83	53.99 - 101.67	<0.001
COVID.19 [Mild]	-36.13	-73.61 – 1.35	0.058
COVID.19 [Moderate]	53.45	17.32 - 89.59	0.005
COVID.19 [Severe]	-15.83	-50.00 - 18.34	0.352
Antigen [Npro Full Ecoli]	-39.05	-64.3613.74	0.003
Antigen [S1Frag Ecoli]	-52.59	-77.9027.28	<0.001
Antigen [S2Frag Ecoli]	-57.60	-82.9132.29	<0.001
Antigen [S2Pri Ecoli]	-52.38	-77.6927.07	<0.001
Antigen [Spro Ecoli]	-56.34	-81.6531.03	<0.001
COVID.19 [Mild] * Antigen [Npro Full Ecoli]	19.82	-18.44 - 58.08	0.309
COVID.19 [Moderate] *Antigen [Npro Full Ecoli]	-71.14	-108.0334.24	<0.001
COVID.19 [Severe] *Antigen [Npro Full Ecoli]	15.05	-19.83 - 49.94	0.397
COVID.19 [Mild] * Antigen [S1Frag Ecoli]	80.40	42.14 - 118.67	<0.001
COVID.19 [Moderate] *Antigen [S1Frag Ecoli]	-52.75	-89.6415.85	0.005
COVID.19 [Severe] *Antigen [S1Frag Ecoli]	44.99	10.10 - 79.88	0.012
COVID.19 [Mild] * Antigen [S2Frag Ecoli]	76.03	37.77 – 114.30	<0.001
COVID.19 [Moderate] *Antigen [S2Frag Ecoli]	-45.17	-82.078.28	0.017
COVID.19 [Severe] *Antigen [S2Frag Ecoli]	58.58	23.69 - 93.46	0.001
COVID.19 [Mild] * Antigen [S2Pri Ecoli]	63.15	24.88 - 101.41	0.001
COVID.19 [Moderate] *Antigen [S2Pri Ecoli]	-56.01	-92.9119.12	0.003
COVID.19 [Severe] *Antigen [S2Pri Ecoli]	59.34	24.45 - 94.23	0.001
COVID.19 [Mild] * Antigen [Spro Ecoli]	63.97	25.71 - 102.24	0.001
COVID.19 [Moderate] *Antigen [Spro Ecoli]	-44.13	-81.027.23	0.019
COVID.19 [Severe] *Antigen [Spro Ecoli]	42.76	7.87 – 77.64	0.016
N _{id}	34		

Table S4. Significance of correlation analysis for first sampling point serum IgG samples binding to antigens with low intensity (3CLike Ecoli, Npro Full Ecoli, S1 Frag Ecoli, S2 Frag Ecoli, S2Pri Ecoli, and Spro Ecoli) compared to non-COVID-19 samples (NC). Bold p value indicates significant correlation.

Observations

	IgG				
Predictors	Estimates	CI	р		
(Intercept)	1229.48	431.16 - 2027.79	0.003		
COVID.19 [Mild]	-589.85	-1845.15 - 665.45	0.345		
COVID.19 [Moderate]	174.53	-1035.83 - 1384.90	0.770		
COVID.19 [Severe]	245.56	-898.94 - 1390.06	0.664		
Antigen [NP Ecoli]	4531.91	3914.78 - 5149.04	<0.001		
Antigen [NP HEK]	-201.15	-818.28 - 415.99	0.522		
Antigen [NP Sf21]	-710.09	-1327.2292.96	0.024		
Antigen [S1 Full HEK]	-1041.49	-1658.62424.36	0.001		
Antigen [S1 Hek]	-994.09	-1611.22376.95	0.002		
Antigen [S1 Sf21]	-410.67	-1027.80 - 206.46	0.192		
COVID.19 [Mild] *Antigen [NP Ecoli]	-2010.93	-2943.941077.91	<0.001		
COVID.19 [Moderate] *Antigen [NP Ecoli]	-1984.75	-2884.361085.13	<0.001		
COVID.19 [Severe] *Antigen [NP Ecoli]	-399.88	-1250.54 - 450.78	0.356		
COVID.19 [Mild] * Antigen [NP HEK]	432.73	-500.29 - 1365.74	0.363		
COVID.19 [Moderate] *Antigen [NP HEK]	-137.27	-1036.88 - 762.35	0.765		
COVID.19 [Severe] *Antigen [NP HEK]	1381.22	530.56 - 2231.88	0.001		
COVID.19 [Mild] * Antigen [NP Sf21]	516.01	-417.01 - 1449.02	0.278		
COVID.19 [Moderate] *Antigen [NP Sf21]	301.42	-598.20 - 1201.04	0.511		
COVID.19 [Severe] *Antigen [NP Sf21]	684.68	-165.98 - 1535.34	0.114		
COVID.19 [Mild] * Antigen [S1 Full HEK]	823.52	-109.49 - 1756.54	0.084		
COVID.19 [Moderate] *Antigen [S1 Full HEK]	-304.15	-1203.77 - 595.46	0.507		
COVID.19 [Severe] *Antigen [S1 Full HEK]	-55.03	-905.69 - 795.62	0.899		
COVID.19 [Mild] * Antigen [S1 HEK]	1081.81	148.80 - 2014.83	0.023		
COVID.19 [Moderate] *Antigen [S1 HEK]	94.92	-804.70 - 994.53	0.836		
COVID.19 [Severe] *Antigen [S1 HEK]	571.77	-278.89 - 1422.42	0.187		
COVID.19 [Mild] * Antigen [S1 Sf21]	563.84	-369.18 - 1496.85	0.236		

Table S5. Significance of correlation analysis for first sampling point serum IgG samples binding to antigens with high intensity (B117 RBD HEK, NP Ecoli, NP HEK, NP Sf21, S1 Full HEK, S1 HEK, and S1 Sf21) compared to non-COVID-19 samples (NC). Bold p value indicates significant correlation.

COVID.19 [Moderate] *Antigen [S1 Sf21]	1187.56	287.95 - 2087.18	0.010
COVID.19 [Severe] *Antigen [S1 Sf21]	1536.96	686.30 - 2387.62	<0.001
N id	34		
Observations	714		

		IgA	
Predictors	Estimates	CI	р
(Intercept)	483.97	192.70 - 775.23	0.001
COVID.19 [Mild]	102.62	-355.23 - 560.47	0.650
COVID.19 [Moderate]	995.78	554.32 - 1437.24	<0.001
COVID.19 [Severe]	0.29	-417.15 - 417.72	0.999
Antigen [Npro Full Ecoli]	-372.02	-682.4461.59	0.019
Antigen [S1Frag Ecoli]	-431.12	-741.55120.70	0.007
Antigen [S2Frag Ecoli]	-287.50	-597.92 - 22.93	0.069
Antigen [S2Pri Ecoli]	-283.09	-593.52 - 27.33	0.074
Antigen [Spro Ecoli]	-443.22	-753.65132.80	0.005
COVID.19 [Mild] * Antigen [Npro Full Ecoli]	206.66	-262.66 - 675.98	0.387
COVID.19 [Moderate] *Antigen [Npro Full Ecoli]	-905.28	-1357.80452.76	<0.001
COVID.19 [Severe] *Antigen [Npro Full Ecoli]	170.46	-257.43 - 598.36	0.434
COVID.19 [Mild] * Antigen [S1Frag Ecoli]	-67.87	-537.19 - 401.45	0.776
COVID.19 [Moderate] *Antigen [S1Frag Ecoli]	-916.57	-1369.09464.05	<0.001
COVID.19 [Severe] *Antigen [S1Frag Ecoli]	16.14	-411.75 - 444.03	0.941
COVID.19 [Mild] * Antigen [S2Frag Ecoli]	176.54	-292.78 - 645.86	0.460
COVID.19 [Moderate] *Antigen [S2Frag Ecoli]	-785.90	-1238.42333.38	0.001
COVID.19 [Severe] *Antigen [S2Frag Ecoli]	282.46	-145.43 - 710.35	0.195
COVID.19 [Mild] *Antigen [S2Pri Ecoli]	8.25	-461.07 - 477.57	0.972
COVID.19 [Moderate] *Antigen [S2Pri Ecoli]	-850.66	-1303.18398.15	<0.001
COVID.19 [Severe] *Antigen [S2Pri Ecoli]	505.82	77.93 - 933.71	0.021
COVID.19 [Mild] *Antigen [Spro Ecoli]	-18.40	-487.72 - 450.92	0.939
COVID.19 [Moderate] *Antigen [Spro Ecoli]	-866.72	-1319.24414.20	<0.001
COVID.19 [Severe] *Antigen [Spro Ecoli]	78.89	-349.00 - 506.78	0.717
N _{id}	34		

Table S6. Significance of correlation analysis for first sampling point serum IgA samples binding to antigens with low intensity (3CLike Ecoli, Npro Full Ecoli, S1 Frag Ecoli, S2 Frag Ecoli, S2Pri Ecoli, and Spro Ecoli) compared to non-COVID-19 (NC) samples. Bold *p* value indicates significant correlation.

Observations

	IgA				
Predictors	Estimates	CI	р		
(Intercept)	2923.08	-3469.64 - 9315.81	0.370		
COVID.19 [Mild]	1262.03	-8790.16 - 11314.22	0.799		
COVID.19 [Moderate]	8141.82	-1550.54 - 17834.17	0.097		
COVID.19 [Severe]	15722.54	6557.67 - 24887.42	0.001		
Antigen [NP Ecoli]	9101.42	4381.07 - 13821.77	<0.001		
Antigen [NP HEK]	804.24	-3916.11 - 5524.59	0.738		
Antigen [NP Sf21]	-744.45	-5464.80 - 3975.90	0.757		
Antigen [S1 Full HEK]	-2210.84	-6931.19 - 2509.51	0.358		
Antigen [S1 Hek]	-2322.92	-7043.28 - 2397.43	0.334		
Antigen [S1 Sf21]	-568.70	-5289.05 - 4151.65	0.813		
COVID.19 [Mild] * Antigen [NP Ecoli]	1777.22	-5359.28 - 8913.71	0.625		
COVID.19 [Moderate] *Antigen [NP Ecoli]	6631.45	-249.58 - 13512.49	0.059		
COVID.19 [Severe] *Antigen [NP Ecoli]	2805.48	-3701.08 - 9312.03	0.397		
COVID.19 [Mild] * Antigen [NP HEK]	2800.65	-4335.85 - 9937.15	0.441		
COVID.19 [Moderate] *Antigen [NP HEK]	2122.99	-4758.05 - 9004.02	0.545		
COVID.19 [Severe] *Antigen [NP HEK]	-4032.48	-10539.03 - 2474.08	0.224		
COVID.19 [Mild] *Antigen [NP Sf21]	1428.80	-5707.70 - 8565.30	0.694		
COVID.19 [Moderate] *Antigen [NP Sf21]	2052.18	-4828.86 - 8933.21	0.558		
COVID.19 [Severe] *Antigen [NP Sf21]	-7715.67	-14222.231209.12	0.020		
COVID.19 [Mild] *Antigen [S1 Full HEK]	-645.71	-7782.21 - 6490.79	0.859		
COVID.19 [Moderate] *Antigen [S1 Full HEK]	-8431.77	-15312.811550.74	0.016		
COVID.19 [Severe] *Antigen [S1 Full HEK]	-15285.98	-21792.548779.43	<0.001		
COVID.19 [Mild] * Antigen [S1 HEK]	4448.66	-2687.84 - 11585.16	0.221		
COVID.19 [Moderate] *Antigen [S1 HEK]	-3845.54	-10726.58 - 3035.49	0.273		
COVID.19 [Severe] *Antigen [S1 HEK]	-1546.90	-8053.46 - 4959.65	0.641		
COVID.19 [Mild] *Antigen [S1 Sf21]	4188.98	-2947.52 - 11325.48	0.250		

Table S7. Significance of correlation analysis for first sampling point serum IgA samples binding to antigens with high intensity (B117 RBD HEK, NP Ecoli, NP HEK, NP Sf21, S1 Full HEK, S1 HEK, and S1 Sf21) compared to non-COVID-19 samples (NC). Bold p value indicates significant correlation.

COVID.19 [Moderate] *Antigen [S1 Sf21]	3432.85	-3448.19 - 10313.88	0.328
COVID.19 [Severe] *Antigen [S1 Sf21]	10480.62	3974.07 - 16987.18	0.002
N _{id}	34		
Observations	714		

		IgM	
Predictors	Estimates	CI	р
(Intercept)	82.21	61.80 - 102.62	<0.001
COVID.19 [Mild]	46.65	14.57 - 78.73	0.006
COVID.19 [Moderate]	-31.78	-62.710.85	0.044
COVID.19 [Severe]	17.79	-11.47 - 47.04	0.224
Antigen [Npro Full Ecoli]	-53.19	-73.0433.34	<0.001
Antigen [S1Frag Ecoli]	-60.68	-80.5340.83	<0.001
Antigen [S2Frag Ecoli]	-47.51	-67.3627.66	<0.001
Antigen [S2Pri Ecoli]	-37.66	-57.5117.81	<0.001
Antigen [Spro Ecoli]	-61.98	-81.8342.13	<0.001
COVID.19 [Mild] * Antigen [Npro Full Ecoli]	-67.02	-97.0337.01	<0.001
COVID.19 [Moderate] *Antigen [Npro Full Ecoli]	15.23	-13.70 - 44.17	0.302
COVID.19 [Severe] *Antigen [Npro Full Ecoli]	-1.35	-28.71 - 26.01	0.923
COVID.19 [Mild] *Antigen [S1Frag Ecoli]	-8.29	-38.30 - 21.72	0.588
COVID.19 [Moderate] *Antigen [S1Frag Ecoli]	34.59	5.65 - 63.53	0.019
COVID.19 [Severe] *Antigen [S1Frag Ecoli]	11.96	-15.40 - 39.32	0.391
COVID.19 [Mild] * Antigen [S2Frag Ecoli]	-47.83	-77.8417.82	0.002
COVID.19 [Moderate] *Antigen [S2Frag Ecoli]	37.51	8.57 - 66.45	0.011
COVID.19 [Severe] *Antigen [S2Frag Ecoli]	-19.80	-47.16 - 7.56	0.156
COVID.19 [Mild] * Antigen [S2Pri Ecoli]	-52.67	-82.6922.66	0.001
COVID.19 [Moderate] *Antigen [S2Pri Ecoli]	38.44	9.50 - 67.37	0.009
COVID.19 [Severe] *Antigen [S2Pri Ecoli]	-17.13	-44.50 - 10.23	0.219
COVID.19 [Mild] * Antigen [Spro Ecoli]	-26.12	-56.13 - 3.89	0.088
COVID.19 [Moderate] *Antigen [Spro Ecoli]	36.00	7.06 - 64.94	0.015
COVID.19 [Severe] *Antigen [Spro Ecoli]	-4.09	-31.46 - 23.27	0.769
N _{id}	34		
Observations	612		

Table S8. Significance of correlation analysis for first sampling point serum IgM samples binding to antigens with low intensity (3CLike Ecoli, Npro Full Ecoli, S1 Frag Ecoli, S2 Frag Ecoli, S2Pri Ecoli, and Spro Ecoli) compared to non-COVID-19 samples (NC). Bold *p* value indicates significant correlation.

	IgM				
Predictors	Estimates	CI	р		
(Intercept)	305.50	-617.69 - 1228.69	0.516		
COVID.19 [Mild]	647.38	-804.29 - 2099.04	0.370		
COVID.19 [Moderate]	1475.50	75.80 - 2875.20	0.039		
COVID.19 [Severe]	1980.25	656.72 - 3303.77	0.005		
Antigen [NP Ecoli]	3772.64	3062.98 - 4482.31	<0.001		
Antigen [NP HEK]	266.87	-442.80 - 976.53	0.461		
Antigen [NP Sf21]	-180.83	-890.49 - 528.84	0.617		
Antigen [S1 Full HEK]	-217.19	-926.86 - 492.47	0.548		
Antigen [S1 Hek]	-179.72	-889.39 - 529.95	0.619		
Antigen [S1 Sf21]	-67.29	-776.95 - 642.38	0.852		
COVID.19 [Mild] * Antigen [NP Ecoli]	-638.41	-1711.32 - 434.51	0.243		
COVID.19 [Moderate] *Antigen [NP Ecoli]	-1286.73	-2321.24252.23	0.015		
COVID.19 [Severe] *Antigen [NP Ecoli]	-629.14	-1607.35 - 349.07	0.207		
COVID.19 [Mild] * Antigen [NP HEK]	-479.05	-1551.97 - 593.86	0.381		
COVID.19 [Moderate] *Antigen [NP HEK]	-1474.74	-2509.25440.23	0.005		
COVID.19 [Severe] *Antigen [NP HEK]	-214.26	-1192.47 - 763.94	0.667		
COVID.19 [Mild] * Antigen [NP Sf21]	-653.36	-1726.28 - 419.55	0.232		
COVID.19 [Moderate] *Antigen [NP Sf21]	-1231.12	-2265.63196.62	0.020		
COVID.19 [Severe] *Antigen [NP Sf21]	-1271.87	-2250.07293.66	0.011		
COVID.19 [Mild] * Antigen [S1 Full HEK]	-292.00	-1364.92 - 780.91	0.593		
COVID.19 [Moderate] *Antigen [S1 Full HEK]	-1532.50	-2567.01497.99	0.004		
COVID.19 [Severe] *Antigen [S1 Full HEK]	-1772.80	-2751.01794.59	<0.001		
COVID.19 [Mild] * Antigen [S1 Hek]	203.68	-869.23 - 1276.60	0.709		
COVID.19 [Moderate] *Antigen [S1 Hek]	-410.73	-1445.24 - 623.78	0.436		
COVID.19 [Severe] *Antigen [S1 Hek]	-375.87	-1354.08 - 602.33	0.451		
COVID.19 [Mild] * Antigen [S1 Sf21]	299.37	-773.55 - 1372.28	0.584		

Table S9. Significance of correlation analysis for first sampling point serum IgM samples binding to antigens with high intensity (B117 RBD HEK, NP Ecoli, NP HEK, NP Sf21, S1 Full HEK, S1 HEK, and S1 Sf21) compared to non-COVID-19 samples (NC). Bold p value indicates significant correlation.

COVID.19 [Moderate] *Antigen [S1 Sf21]	16.73	-1017.78 - 1051.23	0.975
COVID.19 [Severe] *Antigen [S1 Sf21]	1549.98	571.77 – 2528.19	0.002
N id	34		
Observations	714		

Table S10. Serum sample information including follow up samples. Biobank code, COVID-19 disease status of individual at sampling time, days post-symptoms onset at sampling time, biological sex (M, male; F, female), patient age range at time of sampling, and serum IgG, IgA, and IgM concentration. N.d., not detectable; n.a., not assayed.

Code	Disease	Days	Sex	Age range	Serum Ig conc (mg/mL)		
					IgG	IgA	IgM
203-0041-1	Mild	19	М	76-80	32.16	47.21	1.86
203-0041-3	Mild	34	Μ	76-80	5.14	6.53	0.24
203-0077-1	Mild	25	Μ	61-65	3.26	6.07	0.09
203-0077-3	Mild	59	Μ	61-65	1.13	1.63	0.16
203-0054-1	Moderate	9	М	46-50	13.26	4.07	0.31
203-0054-2	Moderate	12	Μ	46-50	113.33	45.92	4.49
203-0004-1	Severe	18	М	41-45	51.30	25.68	2.78
203-0004-2	Severe	29	Μ	41-45	8.11	2.20	0.27
203-0015-2	Severe	16	Μ	66-70	75.25	31.57	4.83
203-0015-4	Severe	145	Μ	66-70	1.13	1.62	0.17
203-0018-1	Severe	19	Μ	66-70	30.53	20.31	0.71
203-0018-4	Severe	271	Μ	66-70	1.00	0.52	n.d.
203-0021-1	Severe	15	Μ	61-65	50.99	12.93	3.71
203-0021-2	Severe	17	Μ	61-65	56.13	2.89	0.35
203-0023-1	Severe	11	F	56-60	58.52	48.17	1.79
203-0023-3	Severe	33	F	56-60	28.49	7.73	0.46
203-0024-1	Severe	31	F	66-70	83.84	29.13	3.61
203-0024-2	Severe	34	F	66-70	n.a.	9.08	1.55
203-0078-2	Severe	9	F	31-35	23.08	8.30	1.80
203-0078-3	Severe	16	F	31-35	66.61	19.34	4.03